Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -472.46% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -16.93% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -111.03% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Pacific Biosciences Of California | 415.91 Mn | 139.95 Mn | 12.84 Mn | 35.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.62% |
| Dec 31, 2025 | -31.34% |
| Sep 30, 2025 | -29.48% |
| Jun 30, 2025 | 34.25% |
| Mar 31, 2025 | 2.46% |
| Dec 31, 2024 | -3.96% |
| Jun 30, 2024 | 29.40% |
| Mar 31, 2024 | -83.49% |
| Dec 31, 2023 | 12.24% |
| Sep 30, 2023 | 79.75% |
| Jun 30, 2023 | -225.49% |
| Mar 31, 2023 | -10.12% |
| Dec 31, 2022 | 194.69% |
| Sep 30, 2022 | 39.97% |
| Jun 30, 2022 | -113.39% |
| Mar 31, 2022 | 3.45% |
| Dec 31, 2021 | 140.59% |
| Jun 30, 2021 | -241.42% |
| Mar 31, 2021 | 45.09% |
| Dec 31, 2020 | -123.89% |